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ABSTRACT
Interferon (IFN) beta-1b was the first disease-
modifying therapy to be approved for the
treatment of multiple sclerosis (MS), and over
21 years of follow-up data demonstrate its
efficacy and long-term safety profile. Following
recent regulatory approvals in the USA and
European Union, IFN beta-1b is now one
of the seven disease-modifying therapies
[intramuscular IFN beta-1a; subcutaneous (SC)
IFN beta-1a; IFN beta-1b SC; glatiramer acetate
SC; oral dimethyl fumarate; oral teriflunomide;
and intravenous alemtuzumab] indicated for
first-line use in relapsing–remitting MS. Here we
review the clinical trial and follow-up data for
IFN beta-1b and discuss factors that clinicians
may consider when selecting this treatment,
both at first line in early MS, and later in the
disease course.
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Typically, multiple sclerosis (MS) manifests
clinically as relapses and disability progression,
and subclinically as disease activity in the form
of white-matter lesions and brain atrophy [1, 2].
The earliest description of MS is dated to the
fourteenth century and disease-modifying
therapy (DMT) remained in the ‘dark ages’
until approval in 1993 of the first interferon
(IFN) treatment for relapsing–remitting MS
(RRMS) [3].
Injected every other day (EOD)
subcutaneously (SC), IFN beta-1b (Betaseron
in the USA, Betaferon in Europe; Bayer) was
joined in 1996 by IFN beta-1a (Avonex; Biogen
Idec), which requires intramuscular (IM)
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injection weekly. A second IFN beta-1a (Rebif;
Merck Serono), which is injected three times a
week SC, gained approval in 2002, only after
head-to-head comparison with Avonex in the
Evidence of Interferon Dose–Response-
European North American Comparative
Efficacy (EVIDENCE; ClincalTrials.gov
#NCT00292266) trial [4]. Extavia (Novartis),
launched in 2009, uses the same biological
ingredient (IFN beta-1b) and administration
route as Betaseron. Initially approved for
relapsing MS or RRMS, the indications for
both IFN beta-1b and beta-1a were expanded
following a series of clinical trials [5–11], to
include clinically isolated syndromes (CIS) and
secondary-progressive MS (SPMS) with relapses.
Glatiramer acetate (GA; Copaxone, Teva), a
synthetic polymer of four amino acids injected
SC, underwent a similar development process,
the original 1996 license for relapsing forms of
MS later being extended to include CIS [12].
Also, an increased-dose regimen with reduced
frequency of administration was recently
approved for GA [13]. As well as the injectable
therapies that have a long history of use
as first-line treatments (Betaseron, Rebif,
Avonex, Copaxone, Extavia––‘BRACE’), several
intravenous or oral therapy options have
become available in recent years: natalizumab
(Tysabri; Biogen Idec, initially 2004, then 2006
following temporary withdrawal for safety
review); alemtuzumab [Lemtrada; Sanofi,
2013––European Union (EU) only]; fingolimod
(Gilenya; Novartis, 2010––different
indications in the USA and the EU);
teriflunomide (Aubagio; Sanofi, 2012), and
dimethyl fumarate (DMF; Tecfidera; Biogen
Idec, 2013) [14].
As one of the mainstays of the BRACE
therapies, self-administered, high-dose, high-
frequency (i.e., 250 lg EOD) IFN beta-1b has a
long-standing efficacy and safety profile, and
remains a first-line option for many patients
with MS [15, 16]. Since the introduction
21 years ago of IFN beta-1b, the process of self-
administration has also evolved from a simple
hypodermic kit to autoinjection devices that
standardize and facilitate delivery of therapy.
The benefits of autoinjection are evident not
only in patients’ preferences for the technology,
but also in improved tolerability of, and
adherence to, treatment [17–21].
Here, we review clinical evidence that
neurologists may consider when
contemplating IFN beta-1b as first-line therapy
in MS, patient groups in which IFN beta-1b
treatment may be particularly appropriate, and
considerations when change of therapy is
indicated for reasons of adherence, tolerability
or disease control. This review article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
HIGH-DOSE, HIGH-FREQUENCY IFN
BETA-1b THERAPY AND BENEFITS
OF EARLY TREATMENT
As well as being the first DMT approved for MS
in the USA (1993) [22] and EU (1995) [23], post-
approval exposure amounting to 1.3 million
patient-years has confirmed the long-term
safety and tolerability of IFN beta-1b [20, 24].
In the EU, the initial treatment indication for
IFN beta-1b has been extended from RRMS and
this label now includes early and later stages of
disease [25].
• CIS: patients with a single demyelinating
event with an active inflammatory process, if
it is severe enough to warrant treatment with
intravenous corticosteroids, if alternative
diagnoses have been excluded, and if they
are determined to be at high risk of
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developing clinically definite multiple
sclerosis (CDMS).
• RRMS: patients with RRMS and two or more
relapses within the last 2 years.
• SPMS: patients with SPMS with active
disease, evidenced by relapses.
Clinically Isolated Syndromes
The 2-year Betaferon in Newly Emerging
Multiple Sclerosis for Initial Treatment
(BENEFIT; ClincalTrials.gov #NCT00185211)
study was the pivotal phase 3 trial of IFN beta-
1b in patients with CIS, comparing the efficacy,
safety, and tolerability of IFN beta-1b with
placebo [6]. In total, 487 patients were
enrolled at 98 centers in Europe, Canada, and
Israel into an initial double-blind, parallel-
group phase in which patients were
randomized 5:3 to IFN beta-1b 250 lg SC EOD
or to matching placebo injections. Early IFN
beta-1b therapy significantly delayed
conversion to MS, irrespective of the endpoint
used; benefits were seen after only a few months
with the McDonald criteria [26], and conversion
to CDMS according to the Poser criteria [27] was
delayed by *1 year [5, 6]. Kaplan–Meier
estimates indicate that the cumulative
probability of developing CDMS was reduced
from 45% in the placebo group to 28% in the
IFN beta-1b group, representing an absolute risk
reduction of 17%; respective rates of
development of McDonald MS were 85% and
69%, a risk reduction of 16%. Compared with
placebo, the relative risk of conversion to CDMS
was reduced by 50% [hazard ratio (HR) 0.50;
95% confidence interval (CI) 0.36–0.70].
Similarly, the relative risk of conversion to
McDonald MS was reduced by 46% (HR 0.54;
95% CI 0.43–0.67) [6].
The delay in conversion was also apparent in
patient subgroups defined according to
measures of clinical and magnetic resonance
imaging (MRI) disease activity at onset.
Consistent with findings reported for other
DMTs [7, 11], there was a trend showing that
the benefits were greater in patients with less
advanced disease than in those with more
advanced disease at baseline [i.e., monofocal
manifestation, absence of gadolinium-
enhancing (Gd?) lesions, fewer than nine T2
lesions], underscoring the importance of early
treatment with immunomodulatory therapies
in patients with CIS [6]. IFN beta-1b prevented
the development of new inflammatory brain
lesions and reduced the burden of disease (T2
lesion volume and count) in patients with a first
event suggestive of MS [6].
Patients completing the placebo-controlled
phase of the BENEFIT study were eligible to
enter a prospectively planned follow-up phase
and subsequent observational extension, in
which patients were observed for up to
8.7 years [5, 28]. All patients who entered the
extension were given the option of treatment
with IFN beta-1b, an alternative DMT, or no
medication. The benefits of early therapy were
still evident after 8 years, as patients initially
randomized to IFN beta-1b treatment had a
significantly lower risk of CDMS compared with
those in whom treatment was delayed by
2 years [28]. Kaplan–Meier estimates indicate
that 55.5% of patients randomized to IFN beta-
1b treatment had progressed to CDMS
compared with 65.8% of patients in the
delayed-therapy group (P = 0.0029). Compared
with the delayed-treatment group, the relative
risk of conversion to CDMS was reduced by 32%
(HR 0.68; 95% CI 0.53–0.88; P = 0.0029) and
time to CDMS was postponed by 3.7 years (50th
percentile) [28]. Annualized relapse rate (ARR)
was a key outcome measure of the extension
study, and relapse outcomes significantly
favored early IFN beta-1b therapy. Over
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8 years, compared with patients in whom
therapy was delayed, patients randomized to
IFN beta-1b had a lower ARR (0.26 versus 0.20,
respectively; P = 0.0012), representing a 23%
reduction in risk (HR 0.77; 95% CI 0.66–0.90;
P = 0.0012). Disability, assessed by the
Expanded Disability Status Scale (EDSS) and
MS Functional Composite scale scores,
remained low and stable in both groups
throughout the 8 years of study, however
patients randomized to IFN beta-1b had higher
(i.e., improved) scores on the Paced Auditory
Serial Addition Test (PASAT) used for cognitive
assessment (P = 0.0453). This low rate of
disability progression was attributed to early
treatment, as patients in both arms received
DMT within 2 years of CIS, which is still quite
early in the disease course [28].
Relapsing–Remitting Multiple Sclerosis
The 2-year Interferon Beta-1b (IFNB) study was
the pivotal phase 3 trial of IFN beta-1b in
patients with RRMS and compared the
efficacy, safety and tolerability of IFN beta-1b
and placebo [29]. The study comprised two
identically designed trials conducted in the USA
and Canada. A total of 372 patients at 11 centers
were enrolled in the double-blind, parallel-
group studies, and were randomized 1:1:1 to
placebo, IFN beta-1b 50 lg SC EOD or IFN beta-
1b 250 lg SC EOD. However, the findings
discussed here are those associated with the
250 lg dose, which subsequently received
regulatory approval [22, 23]. All patients
completing the study could participate in a
double-blind, placebo-controlled, extension
phase of up to 3.5 years; data collected after
the first year of the extension were reported as
3-year data. The IFNB study met both primary
endpoints, demonstrating at 2 years that IFN
beta-1b reduced ARR compared with placebo
(0.84 versus 1.27, respectively; P = 0.0001) and
increased the proportion of exacerbation-free
patients (31% versus 16%, respectively;
P = 0.007). At 3 years, ARR was still lower in
patients receiving IFN beta-1b compared with
placebo (0.84 versus 1.21, respectively;
P = 0.0004), and the proportion of
exacerbation-free patients was still higher, but
not significantly (22% versus 14%, respectively;
P = 0.097). Further measures showed that IFN
beta-1b halved the annual rate of moderate and
severe relapses compared with placebo over
2 years (0.23 versus 0.45, respectively;
P = 0.002) and reduced the number of
hospitalizations over 3 years (37 versus 65,
respectively; P = 0.046). Levels of disability
during the study were stable among the
majority of patients treated with IFN beta-1b
(80%) and placebo (72%); no between-group
difference was observed (P = 0.161) [29].
Assessment of lesion burden (total lesion
area estimated by MRI) at 3 years, found a
median reduction from baseline of 9.3%
associated with IFN beta-1b, compared with an
increase of 15.0% with placebo (P = 0.002).
Acute lesion activity was also reduced by
IFN beta-1b compared with placebo. A cohort
of 52 patients underwent MRI scans every
6 weeks during the first 2 years of the study,
and the median annual rate of active lesions
(defined as new, recurrent or enlarging) was
83% lower in the IFN beta-1b group than the
placebo group (annual rate: 0.5 and 3.0,
respectively; P = 0.0089). Similarly, the median
annual rate of new lesions was 75% lower with
IFN beta-1b than with placebo (annual rate: 0.5
and 2.0, respectively; P = 0.0026) [30].
Among correlation analyses conducted
16 years after randomization, the relationships
between long-term cognitive outcomes and
clinical and MRI characteristics reported at
baseline or during the IFNB trial were examined
918 Adv Ther (2014) 31:915–931
[31]. Cognitive outcomes were assessed using a
‘Cognitive Performance Index’ (the sum of a
patient’s z scores from PASAT, the Symbol Digit
Modality Task, the California Verbal Learning
Test II, the Controlled Oral Word Association
Task, and the Delise–Kaplan Executive Function
System test). Significant correlations were seen
between cognitive outcome and baseline EDSS
(R 0.12; P\0.0001) and baseline T2 lesion
burden (R 0.21; P\0.0001). Multivariate
regression analysis demonstrated that outcomes
during the trial contributed little to prediction of
long-term outcomes [31].
At 21.4 years, the reported follow-up of
IFN beta-1b is the longest for any MS therapy.
A long-term cohort study has evaluated the
effects of early treatment with IFN beta-1b on
all-cause mortality in patients with RRMS who
participated in the IFNB study. At a median of
21.1 years after the time of enrolment in the
original study, 366 of 372 patients (98.4%) were
identified; of these, 81 (22.1%) had died. At
21 years there was a 47% reduction in the
cumulative risk of death (HR 0.53; 95% CI
0.31–0.90; P = 0.0173) among patients
receiving IFN beta-1b during the first 2 years
compared with those initially randomized to
placebo [32]. This treatment effect could have
been attributable to an unexpectedly high
mortality rate in the placebo group, but the
29-year survival rate in this group was shown to
be very similar to that seen in a natural history
MS population from Norway [33].
Sensitivity analyses assessed the robustness
of the results of the 21-year follow-up study,
including assessment of mortality data from
onset of clinical symptoms, rather than from
randomization: IFN beta-1b was associated with
a 50% reduction in all-cause mortality risk
compared with placebo (HR 0.50; 95% CI
0.29–0.85; P = 0.0089). It is difficult to explain
such a long-term effect based on treatment
differences in the first 2 years of study, and it is
notable that in the 16-year follow-up
population [34], median exposure to IFN beta-
1b was greater among patients initially
randomized to IFN beta-1b (8.9 years; range
0.1–17.1 years) than in those initially assigned
to placebo (5.0 years; range 0–12.5 years) [32].
The investigators indicated that they could not
‘‘distinguish between the possibility that the
observed survival benefit was due to an effect of
early treatment and the possibility that the
benefit was due to longer duration of interferon
beta-1b exposure’’ [32]. There are confounding
factors to consider: although a very high
proportion of patients who enrolled in the
IFNB study were identified at the 21-year
follow-up, a relatively high proportion of
those enrolled had discontinued treatment
during the 2-year study [17% (65/372)] and
more than 100 patients failed to complete the
first year of the study extension [29]. In
addition, the primary endpoint of the study
examined all-cause mortality rather than death
attributable to MS [32], although a subsequent
analysis established that 67% of the 81 recorded
deaths were MS-related. Information about
treatment subsequent to IFNB was unavailable
for approximately one third of patients at the
16-year follow-up, although it should be noted
that IFN beta-1b was the only MS DMT available
until 1996, and that the demography of the
patients in the 16-year follow-up was
representative of the original trial population
[34]. Finally, information about treatment was
unavailable for the majority of patients in the
last 5 years of the 21-year follow-up, although
this was not an objective of the analysis [32, 35].
Secondary-Progressive Multiple Sclerosis
Pivotal phase 3 studies of IFN beta-1b versus
placebo have been undertaken in patients with
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active relapsing SPMS in both Europe [8] and
North America [36]. The primary endpoint in
both studies was time to disability progression
over 3 years. Although this was prolonged by
more than 200 days in both studies among
patients receiving IFN beta-1b compared with
placebo, the difference was only significant in
the European study (P\0.001) [8, 36–39]. In
both studies, compared with placebo, IFN beta-
1b reduced ARR over 3 years and prolonged
time to first relapse by more than 200 days
(P B 0.01, all comparisons) [8, 36].
The European study was a double-blind,
parallel-group trial in which patients were
randomized 1:1 to placebo or IFN beta-1b
(250 lg SC EOD). In total, 718 patients were
enrolled in 32 European centers, and the study
met its primary endpoint, demonstrating that
over 3 years, IFN beta-1b prolonged time to
disability progression compared with placebo
in both the prospective interim, and final
analyses (P = 0.0008; P = 0.007, respectively)
[8, 37]. The final analysis of the study showed
that IFN beta-1b reduced mean ARR over 3 years
compared with placebo (0.42 and 0.57,
respectively; P = 0.003), and other prospective
and post hoc analyses reported increases in the
proportion of patients who remained relapse-
free or experienced a decrease in relapse rate
(53.1% versus 45.0%, respectively; P = 0.031);
increases in the proportion of patients
remaining relapse-free, or who either remained
relapse-free or experienced a decrease in relapse
severity, were not significant (P = 0.083;
P = 0.152, respectively) [37].
Examining MRI measures in the European
study, there was no difference in total lesion
volume between the IFN beta-1b and placebo
groups at baseline (P = 0.4117). However,
IFN beta-1b treatment was associated with
reductions in total lesion volume from
baseline at all time points measured during
the study, whereas placebo was associated with
increases from baseline (P\0.0001, for all
between-group comparisons). At the last MRI
scan, the percentage change in mean total
lesion volume from baseline in the two
treatment groups was -2.1% and 15.4%,
respectively (P\0.0001). In a cohort of
patients who underwent monthly MRI scans
(n = 125), the mean cumulative number of both
newly and persistently active lesions associated
with IFN beta-1b treatment was lower than with
placebo. During months 19–24, IFN beta-1b
treatment was associated with a 78% reduction
in newly active lesions (P = 0.0008), and an
88% reduction in persistently active lesions
(P = 0.0004) [38].
In the North American study of patients
with SPMS, patients were randomized 1:1:1 to
receive IFN beta-1b 250 lg SC EOD, IFN beta-1b
160 lg/m2 (body surface area) SC EOD, or
placebo. The primary endpoint was not met at
either dose of IFN beta-1b; when considering
the approved dose of 250 lg, the time taken for
6-month disability progression to be confirmed
among 30% of patients in the placebo groups
(750 days) and IFN beta-1b group (981 days) was
not significantly different (P = 0.606) [36]. This
finding was unaffected by adjustments for
center, baseline EDSS score and duration of
disease. Also, no between-group difference was
seen in the change in mean EDSS score from
baseline to the end of study (P = 0.634) [36].
Differences in disability outcomes between
the European and North American studies in
SPMS may be related to differences in eligibility
criteria and methods of EDSS assessment.
Although the definition of confirmed disability
progression was more stringent in the North
American study (requiring a period of 6 months
before progression could be confirmed rather
than the 3 months in the European study), post
hoc application of the more stringent definition
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to the European data still showed that IFN beta-
1b offered significant improvements versus
placebo in that study.
It is possible that patients in the North
American study were in a more progressive
and less inflammatory stage of disease and
therefore showed a less robust response to
IFN beta-1b than patients in the European
study [36]. However, in a post hoc,
retrospective meta-analysis of the North
American and European trials, there was an
overall risk reduction of about 20% associated
with IFN beta-1b 250 lg SC EOD compared with
placebo for EDSS progression confirmed at
6 months (P = 0.008). The meta-analysis also
indicated that the unexpected disparity
between the studies in disability progression
outcomes was due to differences in patients’
baseline disease activity [39].
Beneficial effects on various relapse-related
endpoints were associated with IFN beta-1b
250 lg SC EOD compared with placebo over
3 years in the North American study: ARR was
43% lower (0.16 versus 0.28, respectively;
P = 0.009); there was a lower rate of moderate
or severe relapses (0.10 versus 0.19, respectively;
P = 0.010); a smaller proportion of patients had
moderate or severe relapses (21% versus 30%,
respectively; P = 0.012); time to first relapse was
greater (1,051 days versus 487 days to the 30%
quantile; P = 0.010); and a greater proportion of
patients were relapse free (71% versus 62%,
respectively; P = 0.018) [36]. Annual MRI data
from the North American study were consistent
with the European study; mean increase in T2
lesion area associated with IFN beta-1b 250 lg
SC EOD was lower than with placebo (107
versus 637 mm2; P\0.001), and in a frequent-
scan cohort (n = 163, Gd? scans every 4 weeks
for 3 years), the annual new active lesion rate
was lower in the IFN beta-1b group than the
placebo group (6.4 versus 18.7, respectively;
P = 0.003) [36].
HEAD-TO-HEAD STUDIES OF IFN
BETA-1b AND OTHER BRACE
THERAPIES
Relatively few head-to-head studies have been
conducted among the BRACE therapies and
discussion here is confined to those involving
IFN beta-1b: versus IFN beta-1a IM, the
Independent Comparison of Interferons
(INCOMIN) trial [40]; versus IFN beta-1a SC
[41]; versus IFN beta-1a both IM and SC [42];
and versus GA, the Betaferon Efficacy Yielding
Outcomes of a New Dose (BEYOND;
ClinicalTrials.gov #NCT00099502) trial [43]
and the Betaseron versus Copaxone in Multiple
Sclerosis with Triple-Dose Gadolinium and
3-Tesla MRI Endpoints (BECOME;
ClinicalTrials.gov #NCT00176592) trial [44].
Conducted over 2 years in patients with
RRMS, the INCOMIN trial compared the
efficacy, safety, and tolerability of high-dose,
high-frequency IFN beta-1b (250 lg SC EOD)
with that of low-dose, low-frequency IFN beta-
1a (Avonex; 30 lg administered IM once a
week). In total, 188 patients were enrolled at
15 centers across Italy, and the primary
endpoint was the proportion of patients who
were relapse-free during the study. Secondary
clinical outcomes included: ARR; the
proportion of patients free from confirmed
disability progression; time to confirmed
disability progression; and EDSS score [40]. For
the majority of clinical measures, IFN beta-1b
was superior to IFN beta-1a IM. Comparing
these two treatment arms, respectively: the
proportion of patients who were relapse-free
was greater over 2 years (51% versus 36%;
P = 0.03); the relative risk of relapse was
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reduced by 24% (HR 0.76; 95% CI 0.59–0.99;
P = 0.03) and mean ARR was reduced (0.5 versus
0.7; P = 0.03); confirmed disability progression
(sustained for 6 months, assessed over 2 years
using the EDSS) was lower (13% versus 30%;
P = 0.005); the relative risk of disability
progression was reduced by 56% (HR 0.44;
95% CI 0.25–0.80; P = 0.005); time to
confirmed disability progression was
prolonged (P\0.01); and mean EDSS score at
2 years was lower (2.1 versus 2.5; P = 0.004)
[40]. Similarly, IFN beta-1b was superior to
IFN beta-1a IM across all MRI measures of
inflammatory activity over 2 years.
Respectively: the proportion of patients free
from new T2 lesions was greater (55% versus
26%; P\0.001); the proportion of patients free
from Gd? lesions was greater (76% versus 49%;
P = 0.001); and the proportion of patients free
from any MRI activity was greater (51% versus
25%; P\0.001). In addition, treatment with
IFN beta-1b showed superiority over IFN beta-1a
IM for these MRI measures over the interim
1-year intervals (months 0–12 and 13–24).
Finally, at 2 years there was a mean decrease
from baseline in the burden of disease (total T2
lesion volume) associated with IFN beta-1b
treatment, and a mean increase associated
with IFN beta-1a treatment (-2.8% versus
11.7%; P\0.0001) [40]. When considering
these findings, it should be borne in mind that
this study was not conducted double-blind,
although the authors state that a centralized
randomization process guarded against
selection bias and MRI-scan readers were
blinded to patients’ treatment allocation. Also,
the fact that all clinical outcomes were assessed
under open-label conditions placed this study at
high risk of interpretive bias [45].
A subsequent study comparing high-dose,
high-frequency and other regimens was
conducted by the Danish Multiple Sclerosis
Group [41]. It was a multicenter, open-label,
randomized 2-year trial in 301 patients with
RRMS comparing IFN beta-1a 22 lg SC once a
week (n = 143) with IFN beta-1b 250 lg SC EOD
(n = 158). The trial also included a cohort of
patients (n = 120), who had declined to be
randomized and received IFN beta-1b 250 lg
SC EOD. Among the randomized patients, no
between-group differences were seen in the
primary endpoints of ARR (-0.01; 95% CI
-0.15 to 0.13) and time to first relapse (IFN
beta-1a versus IFN beta-1b: HR 0.98; 95% CI
0.72–1.32), neither was there a between-group
difference in time to sustained disability
progression (C1.0-point increase in EDSS score,
secondary endpoint: HR 0.91; 95% CI
0.56–1.45) [41]. The lack of a double-blind
design increased the risk of bias as did the fact
that losses to follow-up were not included in the
analysis [45]. Technical difficulties precluded
reporting of a fairly substantial proportion of
the MRI data from this study. No significant
between-group differences were seen at baseline
in mean new/enlarged T2 lesion area (P = 0.39),
or in the mean increase of new/enlarged T2
lesion area from baseline to month 12
(P = 0.099), or from month 12–24 (P = 0.078).
Subjectively, the mean increase in lesional area
associated with IFN beta-1a treatment was
greater than with IFN beta-1b and a similar
trend was reported comparing the respective
proportions of patients with ‘active scans’
(either new or enlarging T2 lesions compared
with a previous study scan or the presence of
Gd? lesions) at 2 years (P = 0.061).
The clinical and MRI efficacy of IFN beta-1b
and GA have been compared in patients with
RRMS in the phase 3 BEYOND trial [43]. In this
trial, 2,244 patients from 26 countries were
randomized 2:2:1 to IFN beta-1b 250 lg SC
EOD, IFN beta-1b 500 lg SC EOD or GA 20 mg
SC daily and followed for up to 3.5 years. At
922 Adv Ther (2014) 31:915–931
2 years, no significant differences in clinical
outcomes (risk of relapse, ARR, proportion of
relapse-free patients, and time to confirmed
disability progression) or most MRI measures
(including mean change in T1-hypointense
lesion volume, and mean change in brain
volume from baseline) were observed between
any two treatment groups [43]. Further,
compared with patients receiving GA, the rate
of evolution of new lesions into permanent
black holes (a marker of irreversible disease) was
similar among those receiving the approved
dose of IFN beta-1b but some benefit was seen
among those receiving the 500 lg dose of IFN
beta-1b (P = 0.0409) [46]. Although no clear
advantage in terms of efficacy was associated
with either treatment, this study does support
the notion that there is little therapeutic benefit
associated with IFN beta-1b dosing at 500 lg
instead of 250 lg SC EOD in early RRMS. The
small, phase 4 BECOME trial also compared IFN
beta-1b with GA [44], enrolling treatment-naı¨ve
patients (n = 75) with CIS or RRMS in North
America. Patients were randomized
approximately 1:1 to IFN 250 lg SC EOD or
GA 20 mg SC daily for 1 year, and subsequently
given the option of continuing for a second
year. A limitation of this study was that, it was
only powered to determine differences in MRI
rather than clinical outcomes, but in common
with BEYOND, few between-group differences
in efficacy were observed [46, 47].
SAFETY AND TOLERABILITY OF IFN
BETA-1b
The fact that IFN beta-1b has the longest follow-
up period among the approved MS DMTs [32],
and that experience of its safety and tolerability
is based on over 1.3 million patient-years of
exposure [20], provides reassurance for
neurologists when considering it as a
treatment option. It was generally well
tolerated in seven pivotal phase 3 studies
spanning patients with CIS [6], RRMS [29, 40,
43], and relapsing SPMS [8, 36]. Summary of the
four placebo-controlled phase 3 studies at the
approved 250 lg dose [6, 8, 25, 29, 36, 48]
revealed the most frequently reported adverse
events (AEs) in patients treated with IFN beta-1b
(n = 1,407) were lymphopenia, injection site
reactions (ISRs), asthenia, flu-like symptoms
(FLS), complex headache, and pain [25, 48].
The most common laboratory abnormalities
were leukopenia and liver enzyme elevations,
which infrequently resulted in dose reduction
or treatment discontinuation (B3% of patients/
study) [48].
Long-term follow-up of patients 16 years
after participation in the phase 3 RRMS study
indicated that patients treated continuously
with IFN beta-1b for the 2 years prior to
the 16-year follow-up visit (n = 69) had
proportionately fewer treatment-related AEs
(including liver enzyme elevations and FLS)
than during the first 2 years of the study.
Chronic liver disease was not identified in any
patient (n = 260) throughout the 16 years of
follow-up [24]. Another potential side-effect of
long-term IFN beta-1b therapy is the production
of neutralizing antibodies (nAbs), which inhibit
interactions at the cell surface between IFN
beta-1b and the type 1 IFN receptor [49].
Occurring in 2–45% of individuals treated
with IFN beta-1b [49], there is a tendency for
nAbs to develop within the first year of therapy
[29], although a proportion of patients revert
spontaneously to seronegative status [50]. The
clinical impact of nAbs remains controversial:
their presence did not affect conversion to
CDMS in the BENEFIT study [5, 28], nor
disability progression in various studies of
RRMS [40, 50] and SPMS [8, 36], but a negative
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association with MRI measures has been found
[50]. The clinical implications of nAbs in MS
therapy have been reviewed recently [49, 51],
but in the absence of specific guideline
recommendations, patient management
should be guided by clinical response rather
than by nAb status.
CONSIDERATIONS IN FIRST-LINE
THERAPY SELECTION
A recent Cochrane review presented a
comprehensive meta-analysis of the efficacy of
immunomodulatory or immunosuppressive
drugs for the treatment of relapsing and
progressive forms of MS [45]. The analysis
focused on relapse rates and disability
progression, but not MRI endpoints, and
concluded that there is moderate-quality
evidence that IFN beta-1b limits the recurrence
of relapses in RRMS over 2 years of therapy
compared with placebo (OR 0.55; 95% CI
0.31–0.99), and placed a moderate level of
confidence in the finding that IFN beta-1b is
more effective than IFN beta-1a IM in reducing
the number of individuals with disability
progression at 2 years (OR 0.35; 95% CI
0.17–0.70). No treatments were found to be
effective at limiting disability progression in
patients with progressive MS, although IFN beta-
1b slightly decreased the odds of clinical relapses
over 3 years [45]. Compared with placebo,
natalizumab and IFN beta-1a SC three times
weekly were found to be superior to other
treatments in reducing relapse rates in RRMS,
and moderate-quality evidence was found for
the effectiveness of these two treatments in
limiting disability progression [45]. The authors
acknowledged that efficacy and benefit/risk
conclusions provided in this meta-analysis are
uncertain beyond 2 years. Furthermore, despite
the fact that relapse rates and disability
progression are well-established measures of
disease activity, it would be interesting to
understand the comparative effects of different
treatments on MRI lesion activity, which is
commonly assessed in both clinical studies and
clinical practice, and which is included in
composite measures of disease activity [52].
In addition to the treatments reviewed by
Filippini and colleagues [45], the oral
treatments teriflunomide [53, 54] and DMF
[55–57] are now approved in both USA and EU
for first-line therapy in MS. Development of
these therapies was originally associated with
other indications (teriflunomide is the active
metabolite of leflunomide, which is indicated in
rheumatoid arthritis [58]; DMF is a component
of Fumaderm [Biogen Idec], which is indicated
in psoriasis), therefore, there is a reasonably
long-standing clinical awareness of possible
tolerability issues or side-effects associated
with these new first-line therapies that may
provide reassurance for their use in MS.
However, it should be noted that linomide
was associated with unexpected serious AEs in
a study of patients with RRMS or SPMS, having
been previously well tolerated in other
indications [59]. While clinical trials have
shown that teriflunomide reduced relapses and
delayed disability progression compared with
placebo [60, 61], a head-to-head study versus
IFN beta-1a SC (TENERE; ClinicalTrials.gov
#NCT00883337) has also shown no superiority
of daily teriflunomide versus high-frequency
IFN in patients with MS [62]. DMF was approved
in 2013 for treatment of relapsing forms of MS
[55, 57], and has shown significant efficacy
compared with placebo (reducing relapses,
delaying disability progression and reducing
the number of Gd? and new or enlarged T2-
weighted hyperintense lesions) [63], although
this benefit in delaying disability progression
was not seen compared with placebo in the
924 Adv Ther (2014) 31:915–931
2-year, placebo-controlled phase 3 study of





The side-effects most frequently reported by
patients following self-injection with IFNs are
ISRs [18], which typically manifest as mild
inflammation, soreness, and pain at the
injection site. Erythema and ulceration can
also occur, but such reactions are rare if
appropriate injection techniques or
autoinjection devices are used [18]. Studies
have shown that injection site pain (ISP) and
ISRs occur significantly more frequently with
IFN beta-1a SC than IFN beta-1b SC [65, 66]. The
randomized, phase 4, open-label, crossover
EPICURE study compared the occurrence of
ISRs when using a standard injection technique
compared with an autoinjector in 294 patients
with RRMS treated with IFN beta-1b [17]. Over a
period of 1 month, the proportion of patients
experiencing ISRs was lower with an
autoinjector than the standard injection
technique (24.1% versus 35.9%; P\0.0001).
The patient- and physician-reported mean ISR
intensity was also reduced when an autoinjector
was used (P\0.0001). Furthermore, more
patients using an autoinjector were ISR-free
(68.1%) than patients using the standard
injection technique (52.4%).
The Betaseron versus Rebif InvestiGating
Higher Tolerability (BRIGHT) study was a large
international, prospective, observational cohort
study that compared the incidence of ISP and
ISRs between IFN beta-1b 250 lg SC EOD and
IFN-beta-1a 44 lg SC three times weekly in
patients with RRMS (n = 454) over a 4–5 week
period [65]. The majority of patients (92%) used
an autoinjector to administer treatment. At all
time points over the 15-injection study period:
more patients were pain-free with IFN beta-1b
than IFN beta-1a (e.g., 42.6% versus 19.7%,
respectively at 30 min post-injection;
P\0.0001); and a greater proportion of
injections were pain-free per patient with
IFN beta-1b than IFN beta-1a (e.g., 79% versus
53.3%, respectively at 30 min post-injection;
P\0.0001). In addition, more patients
receiving IFN beta-1b than IFN beta-1a had no
ISRs (51.8% versus 33.8%; P\0.0001) after the
15-injection period. Pain following injection
had a negative impact on treatment satisfaction
in more patients receiving IFN beta-1a than
receiving IFN beta-1b (35.9% versus 23.1%,
respectively; P = 0.006).
Treatment discontinuation rates among
patients receiving IFN beta range between 14%
and 44% [67]. The occurrence of ISRs is a
common reported reason for treatment
interruption or discontinuation, and presents a
barrier to treatment adherence [18, 67–69]; of
those who interrupt IFN-beta treatment, ISRs
are the reason reported in 12% of patients [18,
70]. The potential impact of ISRs on adherence
is significant as non-adherence is associated
with higher rates of disease relapses and
irreversible MS progression [69]. As well as
adherence, treatment persistence is an
important factor for any first-line injectable
therapy if patients are to benefit from early
intervention. A recent Australian study of
treatment persistence in RRMS patients found
that the median duration of a first-line DMT
was 2.5 years [interquartile range (IQR) 1.0–6.7,
n = 771] [71]. By therapy, the median duration
of persistence was 1.7 years for GA (IQR
0.62–5.2, n = 117), 2.6 years for IFN beta-1a IM
(IQR 1.2–8.5, n = 153), 2.5 years for IFN beta-1a
SC (IQR 0.70–7.1, n = 220) and 2.8 years for
IFN beta-1b (IQR 1.0–5.8, n = 270). Unadjusted
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and adjusted analyses indicated that patients
receiving GA as first-line DMT discontinued
treatment at a greater rate than patients
receiving IFN beta-1a IM (HR 1.74; P = 0.001,
adjusted analysis), IFN beta-1a SC (HR 1.40;
P = 0.03) and IFN beta-1b (HR 1.47; P = 0.01).
ADVANTAGES AND EVOLUTION
OF AUTOINJECTION DEVICES
Self-injection can be inconvenient,
uncomfortable, and daunting for many
patients; these factors should be taken into
account when considering long-term therapy
[19, 20]. Autoinjectors simplify and standardize
the treatment-administration process, improve
treatment satisfaction and convenience for
patients, reduce the number and severity of
ISRs, and are associated with high levels of
adherence compared with manual self-injection
[17, 20, 72, 73]. Trypanophobia is common [20],
but may be countered by the fact that needles
are hidden from view in most autoinjection
devices [72]. Importantly, many patients prefer
autoinjection to conventional manual self-
injection [19, 72]. Such considerations are
important, because they make patients more
likely to adopt and adhere to therapy [19]. In a
prospective, observational study involving 76
patients with RRMS receiving IFN beta-1a 44 lg
three times weekly using an autoinjector, 80.3%
of patients were satisfied with treatment [19].
The advantages of using an autoinjector
reported by patients included convenience
(53%), ease of use (25%), less psychological
trauma and pain, and fewer ISRs (11%, 6%, and
5%, respectively). In a survey of 201 patients
with RRMS, reliability was considered the most
important feature of autoinjectors, followed by
convenience (e.g., ease of use, one-handed
operation, and ability to reach injection sites)
[21]; devices that permit one-handed injection,
at sites that are normally out of reach, mitigate
the over-use of more accessible injection sites,
and thus should reduce skin lesions [21, 72].
Patient-reported compliance and satisfaction
with IFN beta-1b treatment using an
autoinjector was also assessed in a prospective,
12-week, European real-world observational
study (EXCELLENT) conducted in 582 patients
[20]. Over the study period, 96.5% of patients
were compliant with treatment. Compared with
baseline, increased scores were observed in the
Treatment Satisfaction Questionnaire for
Medication-9 convenience domain between
weeks 6 and 12 (P = 0.0009), and in the
5-dimension European Quality of Life
questionnaire between baseline and week 12
(P\0.0001), demonstrating improvements in
patient convenience and health-related quality
of life, respectively. There were also non-
significant increases in global satisfaction and
effectiveness scores. Finally, the prospective,
observational 2-year BetaPlus
(ClinicalTrials.gov #NCT01233245) study
explored the influence of patient supportive
strategies (including autoinjectors, web-based
information, a text-based injection/refill
reminder service, and an interactive patient–
physician program) on adherence in 1,077
patients with RRMS or SPMS who had
switched to IFN beta-1b in the previous
1–3 months [73]. Of the strategies tested,
autoinjector use was found to be the strongest




Probably the most common reasons supporting
the selection of IFN beta-1b are its long history
of safe use and the efficacy of high-dose high-
frequency therapy. Disease stage may also be a
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consideration given the evidence that IFN beta-
1b delayed conversion to CDMS among patients
experiencing CIS; it is also a treatment option to
consider later in the disease course, in relapsing
SPMS, given the reduction in relapse rates
observed during phase 3 trials [8, 36], and the
lower risk of disability progression subsequently
determined across these trials [39]. IFN beta-1b
can be used as a de-escalation option to reduce
the likelihood of certain side-effects associated
with long-term use of more aggressive therapies
although further studies are warranted [74].
Patients’ comorbidities will be considered, for
example, where liver function is compromised,
and the age of the patient may also be a factor,
such as in women of childbearing potential for
whom new oral therapies may be
contraindicated or lacking precedent for safe
use. Patients’ preferences and lifestyles are also
critical to therapy selection, because treatment-
related clinical benefits depend upon patients’
adherence. Any of the injectable therapies may
be a difficult choice to make for patients with
trypanophobia, but support, suitable devices for
self-administration and knowledge of the
effectiveness of the therapy can reduce these
concerns to manageable levels.
Ultimately, it is often the case that therapy
will have to be reconsidered, either because of
adherence/tolerability issues, or because of
disease breakthrough (disability progression,
relapses, MRI lesion activity). Historically, the
options available under these circumstances
were the BRACE therapies, but the advent of
oral and intravenous treatments has broadened
these options considerably. Adherence and
tolerability issues are probably more readily
addressed than disease breakthrough because
the combination of indication, posology and
side-effect profile will often limit the choice of
next-line therapy. Regarding disease
breakthrough, two overarching challenges are
faced by neurologists: first, how to judge what
level of disease breakthrough merits a change of
treatment, particularly if the patient is
accustomed to and comfortable with their
existing therapy; and second, whether to
escalate therapy. The nature of the MS disease
course dictates that while the chosen therapy
must slow or ideally prevent further disease
progression, allowance must be made for the
fact that treatment is life-long. However, the
overall goal is to achieve freedom from disease.
CONCLUSION
Here, we have reviewed the clinical evidence
associated with IFN beta-1b in the treatment of
MS. In addition, improvements in delivery
systems have greatly improved patients’
satisfaction with and adherence to therapy,
compared with traditional manual injection.
Notwithstanding the recent expansion in
therapeutic options, the well-established
efficacy, safety, and tolerability profiles
continue to support the long-term use of IFN
beta-1b, both early in the disease course and
later in the progressive stages of disease.
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